|
Tenax Therapeutics Inc (NASDAQ: TENX) |
|
Tenax Therapeutics Inc
TENX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Tenax Therapeutics Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.72 %
Tenax Therapeutics Inc 's net income grew by 100.84 % in III. Quarter 2024 year on year, above company average,
• More on TENX's Growth
|
|
Tenax Therapeutics Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Company is currently trading with Price to Cash flow multiple of 1.42 in trailing twelve-month period. |
Company |
1 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
• More on TENX's Valuation
|
|
|
|
|
Tenax Therapeutics Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Company is currently trading with Price to Cash flow multiple of 1.42 in trailing twelve-month period. |
Company |
1 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
Tenax Therapeutics Inc Price to Book Ratio is at 1.28 lower than Industry Avg. of 81.17. and higher than S&P 500 Avg. of 0.01
• More on TENX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com